Black Rock Inc. Adc Therapeutics Sa Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Black Rock Inc. holds 3,554,742 shares of ADCT stock, worth $10.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,554,742

Holding current value

$10.7 Million

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.55 - $5.09 $9.06 Million - $18.1 Million	3,554,742 New	3,554,742 $11.2 Million
Q3 2023 Nov 13, 2023	BUY	$0.72 - $2.37 $44,197 - $145,482	61,385 Added 13.1%	529,890 $476,000
Q2 2023 Aug 11, 2023	SELL	$1.9 - $2.66 $317,379 - $444,331	-167,042 Reduced 26.28%	468,505 $1.01 Million
Q1 2023 May 12, 2023	BUY	$1.92 - $5.45 $208,811 - $592,720	108,756 Added 20.64%	635,547 $1.24 Million
Q4 2022 Feb 13, 2023	BUY	$2.87 - $5.24 $283,914 - $518,367	98,925 Added 23.12%	526,791 $2.02 Million
Q3 2022 Nov 14, 2022	SELL	$4.66 - $10.31 $181,451 - $401,450	-38,938 Reduced 8.34%	427,866 $2.06 Million
Q2 2022 Aug 12, 2022	BUY	$5.96 - $14.99 $968,947 - $2.44 Million	162,575 Added 53.44%	466,804 $3.71 Million
Q1 2022 May 12, 2022	BUY	$13.28 - $20.03 $137,740 - $207,751	10,372 Added 3.53%	304,229 $4.47 Million
Q4 2021 Feb 10, 2022	SELL	$19.29 - $31.51 $381,633 - $623,393	-19,784 Reduced 6.31%	293,857 $5.94 Million
Q3 2021 Nov 09, 2021	BUY	$20.45 - $30.0 $263,866 - $387,090	12,903 Added 4.29%	313,641 $8.52 Million
Q2 2021 Aug 11, 2021	BUY	$20.38 - $27.04 $6.13 Million - $8.13 Million	300,738 New	300,738 $7.32 Million

Others Institutions Holding ADCT

# of Institutions

Shares Held

52.8M

Call Options Held

300K

Put Options Held

59.3K

View Full List

About ADC Therapeutics SA

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $234M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

More about ADCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account